Clinical Report: Cyclosporine Solution 0.09% for Uncontrolled Dry Eye

Overview

Revise to emphasize the study's significance and specify the patient population more clearly.

Background

Dry eye disease (DED) is a common condition that can significantly impact patients' quality of life. Traditional treatments, such as cyclosporine emulsion 0.05%, may not adequately control symptoms in all patients. The introduction of cyclosporine solution 0.09% offers a new therapeutic option that may enhance treatment efficacy for those inadequately controlled on lower concentrations.

Data Highlights

Key Findings

• Patients on cyclosporine 0.09% showed significant improvement in corneal fluorescein staining at weeks 4, 8, and 12.
• mSANDE scores also significantly decreased across all time points, indicating reduced symptoms.
• Improvements were consistent regardless of age and sex, suggesting broad applicability of the treatment.
• The study was a phase 4, single-arm, multicenter trial involving patients previously treated with cyclosporine 0.05% for at least 3 months.
• Switching to cyclosporine 0.09% is recommended for patients inadequately controlled on cyclosporine 0.05%.

Clinical Implications

Ophthalmologists should consider switching patients with dry eye disease who are not adequately controlled on cyclosporine emulsion 0.05% to cyclosporine solution 0.09%. This change may lead to improved clinical outcomes and symptom relief, enhancing patient quality of life.

Conclusion

The findings from this study highlight the potential benefits of cyclosporine solution 0.09% in managing dry eye disease, particularly for patients who have not responded adequately to lower concentrations. Further research may solidify its role in clinical practice.

References

1. TFOS DEWS III: Management and Therapy - ScienceDirect, 2025 -- Cyclosporine Solution 0.09% for Dry Eye Disease
2. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease - ScienceDirect, 2018
3. Assessment the Safety of CyclASol compared with Vehicle and Commercially Available 0.05% Cyclosporine in Dry Eye Disease: A Systematic Review and Meta-analysis | Ophthalmology and Therapy
4. Contact Lens Spectrum — discovering dry eye
5. Contact Lens Spectrum — Discovering Dry Eye
6. Contact Lens Spectrum — Dry Eye Dx and Tx
7. Contact Lens Spectrum — ONLINE PHOTO DIAGNOSIS
8. Contact Lens Spectrum — discovering dry eye
9. Contact Lens Spectrum — Discovering Dry Eye
10. Contact Lens Spectrum — Dry Eye Dx and Tx
11. TFOS DEWS III: Management and Therapy - ScienceDirect
12. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease - ScienceDirect
13. Assessment the Safety of CyclASol compared with Vehicle and Commercially Available 0.05% Cyclosporine in Dry Eye Disease: A Systematic Review and Meta-analysis | Ophthalmology and Therapy | Springer Nature Link